Searchable abstracts of presentations at key conferences in endocrinology

ea0035p487 | Diabetes therapy | ECE2014

Changes in insulin sensitivity and DHEAS in type 2 diabetic men treated with liraglutide

Piedrola Gonzalo , Cepero Daniel , Gil Concepcion , Ramirez Jessica , Roa Ricardo

DHEAS, an adrenal steroid which displays antiatherogenic and cardioprotective actions, has been pointed as a marker of insulin sensivity (IS). No studies have inquired the effects of liraglutide on DHEAS levels and its relatioship with IS in patients with type 2 diabetes.Methods: We have studied 12 diabetic male patients (aged 48.6±10.4 years), before and after 6 months of liraglutide therapy. Liraglutide was initiated at 0.6 mg/day for a week and 1...

ea0049gp111 | Diabetes therapy & complications 2 | ECE2017

Hepatic effects of GLP-1 receptor agonist Liraglutide in patients with type 2 diabetes

Hayon Maria , Fernandez Marta , Maraver Silvia , Muros Teresa , Cepero Daniel , Lopez Martin , Quesada Miguel , Pechuan Joaquin , Piedrola Gonzalo

Introduction: The aim of this study was to analyze the effects of Liraglutide in hepatic steatosis as well as clinical and biochemical data before and after 6 months.Methods: We have retrospectively analysed epidemiological, anthropometric and laboratory data of 83 type 2 diabetic patients treated with Liraglutide and followed at different endocrinology units across east Andalusia. We have evaluated nonalcoholic fatty liver disease using liver enzymes an...

ea0056gp11 | Acromegaly | ECE2018

Observational, multicentre study to evaluate the effectiveness in routine clinical practice of Lanreotide Autogel 120 mg at extended dosing intervals (>4 weeks) for the treatment of acromegaly: SOMACROL study

Escola Cristina Alvarez , Fajardo Carmen , Marazuela Monica , Carballido Fernando Cordido , Venegas Eva Maria , Velasco Pedro de Pablos , Maroto Gonzalo Piedrola , Marquez Ma del Pilar Olvera , de Paz Isabel Pavon , Carvalho Davide , Romero Carme , De la Cruz Guillermo , Bernabeu Ignacio

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...